Chitose Laboratory Corp. and FUJIFILM Biosciences Inc. have announced a strategic partnership aimed at advancing innovation in biopharmaceutical manufacturing. The alliance will combine CHITOSE's experience in cell line development, specifically with its CHO-MK cells, and FUJIFILM Biosciences' capabilities in culture media development and manufacturing.
The collaboration seeks to accelerate the production processes for biopharmaceuticals by integrating CHITOSE's proprietary CHO-MK cell line and high-expression vector system with FUJIFILM Biosciences’ GMP-manufactured AdaptPD CHO-MK Platform Media. This integration is expected to result in higher productivity and improved quality of antibody and recombinant protein products.
According to both companies, the growth characteristics of CHO-MK cells in optimized media have enabled the generation of highly productive cells, which can help reduce manufacturing time and costs while ensuring product consistency.
Yutaka Yamaguchi, chairman and chief executive officer at FUJIFILM Biosciences, stated: "We're excited about this strategic alliance as it underscores a shared vision of advancing therapeutic development by providing solutions designed to meet the growing demand for making biopharmaceuticals more accessible for treating conditions. FUJIFILM Biosciences forms alliances with like-minded companies like CHITOSE to drive meaningful progress and to create a lasting impact across life sciences."
The partnership aims to support the development of new therapies globally, improving access to essential treatments for patients worldwide.
